Critical Flicker Fusion — CPB 0860 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0860 for critical flicker fusion testing, effective January 5, 2026. The policy classifies this test as experimental and investigational across all covered indications — meaning claims will deny. Here's what billing teams need to know.

Critical flicker fusion (CFF) testing has never been a high-volume billing item, but if it shows up in your ophthalmology, neurology, or hepatology workflow, Aetna's updated coverage policy draws a clear line: this test does not meet medical necessity under any of the listed indications. The update affects procedures tied to keratoprosthesis (CPT 65770) and select cataract surgery codes in the 66820s through 66900s as listed in CPB 0860, along with related surgical services. If your practice uses CFF testing to guide surgical decisions or monitor neurological drug effects, you need to understand this policy before billing — or you will face claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Critical Flicker Fusion — CPB 0860
Policy Code	CPB 0860
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	Medium
Specialties Affected	Ophthalmology, Neurology, Hepatology, Pharmacology
Key Action	Audit any claims using CFF testing to support surgical or diagnostic coding; expect denial for all listed indications under Aetna

---

Aetna Critical Flicker Fusion Coverage Criteria and Medical Necessity Requirements 2026

The short version: Aetna does not cover critical flicker fusion testing. Full stop.

CPB 0860 classifies CFF as experimental, investigational, or unproven for every indication listed in the policy. There are no approved indications. There is no pathway to coverage by meeting medical necessity criteria, because Aetna's position is that the clinical evidence does not support CFF as an effective diagnostic or predictive tool for any of the conditions addressed in this policy.

This is worth saying plainly. Some payer coverage policies have a covered tier and an excluded tier. This one does not. Every indication Aetna names in this policy lands in the experimental bucket. If you are ordering CFF testing and billing Aetna for related services — or using CFF results to justify surgical procedures like keratoprosthesis (CPT 65770) or select cataract surgery codes — you are working without a coverage floor.

The effective date of January 5, 2026, means this policy is already active. If your team has been billing for services tied to CFF testing results, audit those claims now.

---

Aetna Critical Flicker Fusion Exclusions and Non-Covered Indications

Aetna's updated critical flicker fusion coverage policy is unusual in that the exclusion list is the whole policy. There is no covered use case. Every indication listed below is classified as experimental, investigational, or unproven.

Here is what Aetna specifically excludes under CPB 0860:

1. Neurotoxic adverse event monitoring in pharmacology and visual fatigue
Some clinical teams use CFF to detect early neurotoxic effects of drugs. Aetna does not accept this as a proven application. If your oncology or neurology practice uses CFF to monitor patients on neurotoxic medications, those results cannot form the basis for a covered Aetna claim.

2. Diagnosis of low-grade (minimal) hepatic encephalopathy
This is a notable exclusion. CFF has been studied as a non-invasive tool for detecting minimal hepatic encephalopathy — a real diagnostic challenge in hepatology. Aetna's position is that the evidence does not support routine clinical use. Hepatology and gastroenterology practices managing cirrhosis patients should note this directly.

3. Diagnosis of visual acuity
Standard visual acuity has established, covered diagnostic pathways. Aetna does not recognize CFF as a valid substitute or adjunct for visual acuity diagnosis.

4. Differential diagnosis of demyelinating optic neuritis vs. ischemic optic neuropathy
Neuro-ophthalmology teams sometimes look at CFF as a way to distinguish between these two conditions. Aetna says the clinical evidence is not there. Claims using CFF results to support this differential diagnosis will not fly under Aetna billing guidelines.

5. Prediction of executive dysfunction
Neuropsychology and neurology practices exploring CFF as a predictor of executive dysfunction should treat this application as non-covered under Aetna.

6. Prediction of visual outcomes in keratoprosthesis surgery and cataract/macular disease surgery
This is where it gets most relevant to surgical billing. If your ophthalmology team uses CFF testing to predict outcomes before keratoprosthesis (CPT 65770) or select cataract surgery codes as listed in CPB 0860, Aetna will not treat that testing as a valid covered service. It will not support medical necessity documentation for the surgical codes, either.

---

Coverage Indications at a Glance

---

Aetna Critical Flicker Fusion Billing Guidelines and Action Items 2026

This policy is active as of January 5, 2026. Work through these steps now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Critical Flicker Fusion Under CPB 0860

These codes appear in the Aetna CPB 0860 policy as related codes. None of these procedures are covered when CFF testing is used to establish medical necessity, predict outcomes, or support the diagnosis.

CPT Codes — Surgical Procedures Related to CPB 0860

Note: The Aetna policy lists 169 total CPT codes. The table above reflects all codes explicitly provided in the policy data. Consult the full CPB 0860 policy at the Aetna source for the complete list.

HCPCS Codes

The policy data does not list specific HCPCS codes for CPB 0860.

ICD-10-CM Diagnosis Codes

The Aetna CPB 0860 policy lists 125 ICD-10-CM codes in total. The full code-level data was not available in the policy extract. Check the full CPB 0860 policy document directly at the Aetna source for the complete ICD-10-CM code list.

---